Freenome is a leading brand in the field of early cancer detection. They are dedicated to developing next-generation blood tests that can detect cancer at its earliest, most treatable stages. The company's approach focuses on using a standard blood draw to identify biomarkers from both tumor and non-tumor-derived sources, allowing them to detect the body's earliest warning signs of cancer.

Freenome's blood tests are being developed using their innovative multiomics platform, which combines expertise in molecular biology and machine learning. This platform enables them to analyze billions of circulating biomarkers and identify cancer-associated patterns. By decoding these hidden patterns, Freenome is paving the way for more accurate and accessible cancer detection.

With a commitment to advancing early cancer detection, Freenome aims to make a significant impact in the fight against cancer. They prioritize making their tests accessible to everyone, as they believe there is no blueprint for putting an end to cancer. Stay connected with Freenome for the latest news on clinical trials, publications, and more.

Privacy is respected, ensuring your information remains confidential